60% of colorectal cancer patients can obtain satisfactory treatment effect At the recent Colorectal Cancer Individualized Treatment China Forum, the first K-ras gene research data related to the development of colorectal cancer was disclosed, showing that 65.9% of colorectal cancer patients in China have wild-type genotype, and through the most advanced K-ras gene testing combined with individualized targeted therapy, about 60% of K-ras wild-type colorectal cancer patients can obtain satisfactory treatment effect. The most advanced K-ras gene testing combined with individualized targeted therapy can achieve satisfactory treatment results. At present, surgery is still the only means to cure colorectal cancer, but surgery alone is not enough to achieve complete cure for some patients, especially those in the middle and late stages, and adjuvant radiotherapy and pharmacotherapy are needed. Drug therapy includes traditional chemotherapy and targeted therapy. Targeted therapy refers to the action of anti-tumor drugs with different specific target sites of tumor to kill tumor cells, which has less impact on normal tissues and is the most ideal mode of tumor treatment. Genetic testing and screening is imperative During long-term observation and clinical treatment, the medical profession gradually found that patients of the same gender, the same age, and even the same stage, with the same drugs, some have good efficacy and some have poor efficacy, indicating that there are individual differences in colorectal cancer patients. Therefore, only by individualized treatment with different treatment for the same disease, can we select the right drug for different types of patients, and K-ras gene has become the first biomarker that can be used to select targeted drugs for colorectal cancer. Molecular biology studies have found that colorectal carcinogenesis is related to genes, such as point mutations in K-ras gene, mutations in growth inhibitor gene P53, loss of APC gene, and mutations in DCC gene. In recent years, a lot of research work on K-ras gene has been carried out in the international medical community. Researchers found that K-ras gene is like a “switch” in our body, which plays an important role in regulating the signaling pathway of tumor cell growth and angiogenesis, etc. Normal K-ras gene can inhibit tumor cell growth, but once mutation occurs, it will continue to stimulate cell growth and disrupt the growth pattern, thus leading to tumor development. Once a mutation occurs, it will continue to stimulate cell growth and disrupt the growth pattern, thus leading to the development of tumor. K-ras gene test is the most direct and effective method for doctors to understand the oncogene status of colorectal cancer patients, and in developed countries such as Europe and the United States, K-ras test has become a mandatory routine examination before medical treatment for colorectal cancer patients. More importantly, it can help screen for EGFR-targeted drug therapy and individualize the treatment of colorectal cancer patients, thus achieving a good prognosis and prolonging the survival of patients, while significantly reducing unnecessary treatment costs and toxic side effects. K-ras genes are classified into two types: normal state (called wild type) and abnormal state (mutant). A large phase III clinical trial (CRYSTAL) involving scientists from multiple countries showed that for patients with K-ras wild-type metastatic colorectal cancer, first-line chemotherapy with cetuximab (EPITOL) was 59% effective, with a 32% reduction in the risk of tumor progression, an overall disease control rate of nearly 90%, and a significantly longer disease-free survival. 75 countries have 75 countries have approved Epiduo for the treatment of colorectal cancer. The significance of the K-ras gene test is that if the K-ras gene is wild type, the patient can be treated with individualized comprehensive treatment plan by adding Epiduo to chemotherapy. The significance of K-ras gene test is that if the K-ras gene of colorectal cancer patients is wild type, about 60% of colorectal cancer patients can get good treatment effect through individualized comprehensive treatment plan, which is based on chemotherapy plus Epiduo targeted therapy.